Found: 105
Select item for more details and to access through your institution.
Circulating microRNAs in association with pancreatic cancer risk within 5 years.
- Published in:
- International Journal of Cancer, 2024, v. 155, n. 3, p. 519, doi. 10.1002/ijc.34956
- By:
- Publication type:
- Article
Evolving or immutable - phase I solid tumor trials in the era of precision oncology.
- Published in:
- Investigational New Drugs, 2024, v. 42, n. 3, p. 326, doi. 10.1007/s10637-024-01445-z
- By:
- Publication type:
- Article
A phase I study of ATR inhibitor gartisertib (M4344) as a single agent and in combination with carboplatin in patients with advanced solid tumours.
- Published in:
- British Journal of Cancer, 2024, v. 130, n. 7, p. 1131, doi. 10.1038/s41416-023-02436-2
- By:
- Publication type:
- Article
Ibrutinib combination therapy for advanced gastrointestinal and genitourinary tumours: results from a phase 1b/2 study.
- Published in:
- BMC Cancer, 2023, v. 23, n. 1, p. 1, doi. 10.1186/s12885-023-11539-1
- By:
- Publication type:
- Article
Management of Patients With Pancreatic Cancer Using the "Right Track" Model.
- Published in:
- Oncologist, 2023, v. 28, n. 7, p. 584, doi. 10.1093/oncolo/oyad080
- By:
- Publication type:
- Article
Cancers of the Pancreas Update 2023.
- Published in:
- Clinical Colorectal Cancer, 2023, v. 22, n. 1, p. 1, doi. 10.1016/j.clcc.2023.02.002
- By:
- Publication type:
- Article
Correlates of Taxane-Induced Neuropathy, an Electronic Health Record Based Observational Study.
- Published in:
- Cancers, 2023, v. 15, n. 3, p. 754, doi. 10.3390/cancers15030754
- By:
- Publication type:
- Article
Safety and Efficacy of Avelumab in Small Bowel Adenocarcinoma.
- Published in:
- 2022
- By:
- Publication type:
- journal article
Racial/Ethnic Disparities in Mortality Related to Access to Care for Major Cancers in the United States.
- Published in:
- Cancers, 2022, v. 14, n. 14, p. N.PAG, doi. 10.3390/cancers14143390
- By:
- Publication type:
- Article
First-in-human trial exploring safety, antitumor activity, and pharmacokinetics of Sym013, a recombinant pan-HER antibody mixture, in advanced epithelial malignancies.
- Published in:
- Investigational New Drugs, 2022, v. 40, n. 3, p. 586, doi. 10.1007/s10637-022-01217-7
- By:
- Publication type:
- Article
Phase I trial of ATM inhibitor M3541 in combination with palliative radiotherapy in patients with solid tumors.
- Published in:
- Investigational New Drugs, 2022, v. 40, n. 3, p. 596, doi. 10.1007/s10637-022-01216-8
- By:
- Publication type:
- Article
Author Correction: Phase I trial of ATM inhibitor M3541 in combination with palliative radiotherapy in patients with solid tumors.
- Published in:
- 2022
- By:
- Publication type:
- Correction Notice
Trends in the Incidence and Treatment of Early-Onset Pancreatic Cancer.
- Published in:
- Cancers, 2022, v. 14, n. 2, p. 283, doi. 10.3390/cancers14020283
- By:
- Publication type:
- Article
External Validation of a Clinical Score for Patients With Neuroendocrine Tumors Under Consideration for Peptide Receptor Radionuclide Therapy.
- Published in:
- JAMA Network Open, 2022, v. 5, n. 1, p. e2144170, doi. 10.1001/jamanetworkopen.2021.44170
- By:
- Publication type:
- Article
First‐in‐human PET imaging and estimated radiation dosimetry of L‐[5‐ 11C]‐glutamine in patients with metastatic colorectal cancer.
- Published in:
- Journal of Nuclear Medicine, 2021, v. 62, n. 12, p. 1, doi. 10.2967/jnumed.120.261594
- By:
- Publication type:
- Article
First‐in‐human PET imaging and estimated radiation dosimetry of L‐[5‐<sup>11</sup>C]‐glutamine in patients with metastatic colorectal cancer.
- Published in:
- Journal of Nuclear Medicine, 2021, v. 62, n. 11, p. 1, doi. 10.2967/jnumed.120.261594
- By:
- Publication type:
- Article
Comparison of Design, Eligibility, and Outcomes of Neuroendocrine Neoplasm Trials Initiated From 2000 to 2009 vs 2010 to 2020.
- Published in:
- JAMA Network Open, 2021, v. 4, n. 10, p. e2131744, doi. 10.1001/jamanetworkopen.2021.31744
- By:
- Publication type:
- Article
Racial disparity in taxane‐induced neutropenia among cancer patients.
- Published in:
- Cancer Medicine, 2021, v. 10, n. 19, p. 6767, doi. 10.1002/cam4.4181
- By:
- Publication type:
- Article
First‐in‐human PET imaging and estimated radiation dosimetry of L‐[5‐<sup>11</sup>C]‐glutamine in patients with metastatic colorectal cancer.
- Published in:
- Journal of Nuclear Medicine, 2021, v. 62, n. 10, p. 1, doi. 10.2967/jnumed.120.261594
- By:
- Publication type:
- Article
First-in-human PET imaging and estimated radiation dosimetry of L-[5-<sup>11</sup>C]-glutamine in patients with metastatic colorectal cancer.
- Published in:
- Journal of Nuclear Medicine, 2021, v. 62, n. 8, p. 1, doi. 10.2967/jnumed.120.261594
- By:
- Publication type:
- Article
Mismatch Repair (MMR) Gene Alteration and BRAF V600E Mutation Are Potential Predictive Biomarkers of Immune Checkpoint Inhibitors in MMR‐Deficient Colorectal Cancer.
- Published in:
- Oncologist, 2021, v. 26, n. 8, p. 668, doi. 10.1002/onco.13741
- By:
- Publication type:
- Article
First-in-human PET imaging and estimated radiation dosimetry of L-[5-<sup>11</sup>C]-glutamine in patients with metastatic colorectal cancer.
- Published in:
- Journal of Nuclear Medicine, 2021, v. 62, n. 7, p. 1, doi. 10.2967/jnumed.120.261594
- By:
- Publication type:
- Article
First-in-human PET imaging and estimated radiation dosimetry of L-[5-<sup>11</sup>C]-glutamine in patients with metastatic colorectal cancer.
- Published in:
- Journal of Nuclear Medicine, 2021, v. 62, n. 6, p. 1, doi. 10.2967/jnumed.120.261594
- By:
- Publication type:
- Article
First-in-human PET imaging and estimated radiation dosimetry of L-[5-<sup>11</sup>C]-glutamine in patients with metastatic colorectal cancer.
- Published in:
- Journal of Nuclear Medicine, 2021, v. 62, n. 5, p. 1, doi. 10.2967/jnumed.120.261594
- By:
- Publication type:
- Article
Safety and Efficacy of Andecaliximab (GS‐5745) Plus Gemcitabine and Nab‐Paclitaxel in Patients with Advanced Pancreatic Adenocarcinoma: Results from a Phase I Study.
- Published in:
- Oncologist, 2020, v. 25, n. 11, p. 954, doi. 10.1634/theoncologist.2020-0474
- By:
- Publication type:
- Article
A Phase II, Single‐Arm, Open‐Label, Bayesian Adaptive Efficacy and Safety Study of PBI‐05204 in Patients with Stage IV Metastatic Pancreatic Adenocarcinoma.
- Published in:
- Oncologist, 2020, v. 25, n. 10, p. e1446, doi. 10.1634/theoncologist.2020-0440
- By:
- Publication type:
- Article
Impact of liver tumour burden, alkaline phosphatase elevation, and target lesion size on treatment outcomes with 177Lu-Dotatate: an analysis of the NETTER-1 study.
- Published in:
- European Journal of Nuclear Medicine & Molecular Imaging, 2020, v. 47, n. 10, p. 2372, doi. 10.1007/s00259-020-04709-x
- By:
- Publication type:
- Article
Immune‐Related Adverse Events and Immune Checkpoint Inhibitor Efficacy in Patients with Gastrointestinal Cancer with Food and Drug Administration‐Approved Indications for Immunotherapy.
- Published in:
- Oncologist, 2020, v. 25, n. 8, p. 669, doi. 10.1634/theoncologist.2019-0637
- By:
- Publication type:
- Article
Immunotherapy After Immunotherapy: Response Rescue in a Patient With Microsatellite Instability-high Colorectal Cancer Post-Pembrolizumab.
- Published in:
- 2020
- By:
- Publication type:
- case study
A phase 1b dose escalation study of Wnt pathway inhibitor vantictumab in combination with nab-paclitaxel and gemcitabine in patients with previously untreated metastatic pancreatic cancer.
- Published in:
- Investigational New Drugs, 2020, v. 38, n. 3, p. 821, doi. 10.1007/s10637-019-00824-1
- By:
- Publication type:
- Article
Perioperative Gemcitabine + Erlotinib Plus Pancreaticoduodenectomy for Resectable Pancreatic Adenocarcinoma: ACOSOG Z5041 (Alliance) Phase II Trial.
- Published in:
- Annals of Surgical Oncology: An Oncology Journal for Surgeons, 2019, v. 26, n. 13, p. 4489, doi. 10.1245/s10434-019-07685-1
- By:
- Publication type:
- Article
First-in-Human Phase I Study of Aprutumab Ixadotin, a Fibroblast Growth Factor Receptor 2 Antibody-Drug Conjugate (BAY 1187982) in Patients with Advanced Cancer.
- Published in:
- 2019
- By:
- Publication type:
- journal article
PD-L1 Expression Patterns in Microsatellite Instability-High Intestinal Adenocarcinoma Subtypes.
- Published in:
- 2019
- By:
- Publication type:
- journal article
Correction: A phase 2 randomised study of veliparib plus FOLFIRI±bevacizumab versus placebo plus FOLFIRI±bevacizumab in metastatic colorectal cancer.
- Published in:
- 2019
- By:
- Publication type:
- corrected article
A Phase 1b/2 Study of the Bruton Tyrosine Kinase Inhibitor Ibrutinib and the PD-L1 Inhibitor Durvalumab in Patients with Pretreated Solid Tumors.
- Published in:
- Oncology, 2019, v. 97, n. 2, p. 102, doi. 10.1159/000500571
- By:
- Publication type:
- Article
Phase I study combining the aurora kinase a inhibitor alisertib with mFOLFOX in gastrointestinal cancer.
- Published in:
- Investigational New Drugs, 2019, v. 37, n. 2, p. 315, doi. 10.1007/s10637-018-0663-0
- By:
- Publication type:
- Article
A phase 2 randomised study of veliparib plus FOLFIRI±bevacizumab versus placebo plus FOLFIRI±bevacizumab in metastatic colorectal cancer.
- Published in:
- 2019
- By:
- Publication type:
- journal article
The eye of the beholder: orbital metastases from midgut neuroendocrine tumors, a two institution experience.
- Published in:
- 2018
- By:
- Publication type:
- journal article
Correction to: Phase I study combining the aurora kinase a inhibitor alisertib with mFOLFOX in gastrointestinal cancer.
- Published in:
- Investigational New Drugs, 2018, v. 36, n. 6, p. 1158, doi. 10.1007/s10637-018-0679-5
- By:
- Publication type:
- Article
Harnessing the Immune System in Pancreatic Cancer.
- Published in:
- 2018
- By:
- Publication type:
- journal article
First-in-human phase I dose escalation study of MK-8033 in patients with advanced solid tumors.
- Published in:
- Investigational New Drugs, 2018, v. 36, n. 5, p. 860, doi. 10.1007/s10637-018-0567-z
- By:
- Publication type:
- Article
Dual Src and EGFR inhibition in combination with gemcitabine in advanced pancreatic cancer: phase I results.
- Published in:
- Investigational New Drugs, 2018, v. 36, n. 3, p. 442, doi. 10.1007/s10637-017-0519-z
- By:
- Publication type:
- Article
A First‐in‐Human Phase I Study of OPB‐111077, a Small‐Molecule STAT3 and Oxidative Phosphorylation Inhibitor, in Patients with Advanced Cancers.
- Published in:
- Oncologist, 2018, v. 23, n. 6, p. 658, doi. 10.1634/theoncologist.2017-0325
- By:
- Publication type:
- Article
Current Concepts in the Treatment of Resectable Pancreatic Cancer.
- Published in:
- Current Oncology Reports, 2018, v. 20, n. 5, p. 1, doi. 10.1007/s11912-018-0685-y
- By:
- Publication type:
- Article
A phase 1 dose-escalation study of veliparib with bimonthly FOLFIRI in patients with advanced solid tumours.
- Published in:
- 2018
- By:
- Publication type:
- journal article
Frequent <italic>BRAF</italic> mutations suggest a novel oncogenic driver in colonic neuroendocrine carcinoma.
- Published in:
- Journal of Surgical Oncology, 2018, v. 117, n. 2, p. 284, doi. 10.1002/jso.24834
- By:
- Publication type:
- Article
An Intergroup Randomized Phase II Study of Bevacizumab or Cetuximab in Combination with Gemcitabine and in Combination with Chemoradiation in Patients with Resected Pancreatic Carcinoma: A Trial of the ECOG-ACRIN Cancer Research Group (E2204).
- Published in:
- Oncology, 2018, v. 94, n. 1, p. 39, doi. 10.1159/000480295
- By:
- Publication type:
- Article
Could the PD-1 Pathway Be a Potential Target for Treating Small Intestinal Adenocarcinoma?
- Published in:
- 2017
- By:
- Publication type:
- journal article
A Phase Ib Dose-Escalation Study of the Safety, Tolerability, and Pharmacokinetics of Cobimetinib and Duligotuzumab in Patients with Previously Treated Locally Advanced or Metastatic Cancers with Mutant KRAS.
- Published in:
- Oncologist, 2017, v. 22, n. 9, p. 1024, doi. 10.1634/theoncologist.2017-0175
- By:
- Publication type:
- Article
Phase II study of the Multikinase inhibitor of angiogenesis, Linifanib, in patients with metastatic and refractory colorectal cancer expressing mutated KRAS.
- Published in:
- Investigational New Drugs, 2017, v. 35, n. 4, p. 491, doi. 10.1007/s10637-017-0458-8
- By:
- Publication type:
- Article